Loading
Yanuki
SUBCATEGORY FEED
Novo Nordisk's Wegovy Sales Jump, Boosting 2026 Outlook | Wegovy Approved for Liver Disease: A Breakthrough for MASH Treatment | Novo Nordisk's Wegovy Sales Jump, Boosting 2026 Outlook | Wegovy Approved for Liver Disease: A Breakthrough for MASH Treatment

Health & Science / Pharmaceuticals

Novo Nordisk's Wegovy Sales Jump, Boosting 2026 Outlook

Novo Nordisk (NVO) has revised its full-year guidance for 2026 following stronger-than-expected sales of its Wegovy weight-loss pill. The company's stock experienced a notable increase as the market responded positively to the news.

Novo Nordisk's Wegovy Sales Jump, Boosting 2026 Outlook Image via CNBC
Wegovy pill sales smash forecasts, sending Novo Nordisk stock 7% higher
Pharmaceuticals Weather